Monitor this situation.

Unsubscribe anytime.

[SITUATION] · [ACTIVE] · [HEALTH]

239 clusters · 872 sources · 145 days · First seen 5 months ago · Last updated 1 day ago

GLP-1 drugs: clinical trends, safety, and market shifts

Overview

Since mid-2026, the expansion of GLP-1 agents for obesity has been accompanied by intensified safety monitoring and evolving clinical data. While research suggests secondary benefits—including a 21% lower risk of fragility fractures in older adults and potential liver protection—new physiological and economic concerns have emerged.

Clinical applications are expanding. The FDA has approved Mounjaro for heart attack and stroke risk reduction in high-risk type 2 diabetes patients, and Wegovy for cardiovascular risk reduction in adults with obesity. Recent data published in Nature Communications suggests a potential link between GLP-1 use and a reduced risk of serious infections, such as tuberculosis. Additionally, clinical trials for tirzepatide indicate significant improvements in obstructive sleep apnea, with 42% to 50% of participants achieving symptom remission.

However, new safety and usage concerns have surfaced. A study led by NYU Langone Health, published in the Journal of Investigative Dermatology, identified a genetic link between GLP-1 receptor agonists and an increased risk of male-pattern baldness. Using Mendelian randomization, researchers found that men with genetic variants predicting higher activity of the GLP1R gene face an additional 7% risk of androgenetic alopecia. Furthermore, in the United States, prescriptions for children under 12 have increased more than 300-fold since 2019, prompting calls for long-term monitoring of younger populations.

Economic and industrial shifts continue to accelerate. In the United States, the rise of these medications is impacting the fashion and food sectors. Major retailers like H&M have reduced inventories of larger clothing sizes due to declining demand. Simultaneously, the food industry is seeing a shift toward nutrient density; Groupe Bel reported that reduced appetite is driving demand for smaller portions and high-protein products.

Entities

Novo Nordisk · Wegovy · Ozempic · Eli Lilly · Mounjaro

Claims

What the coverage asserts, and how many sources carry each claim.

Coverage disagrees

Sources make claims that cannot both be true. CLSTR reports the disagreement; it does not decide who is right.

"Mounjaro (tirzepatide) had 120 reported deaths and 106,309 adverse reaction reports."

vs

"For tirzepatide (Mounjaro), 106,189 adverse reactions were reported, including 120 deaths."

The claims provide different totals for Mounjaro (tirzepatide) adverse reaction reports (106,189 vs 106,309).
"Wegovy (semaglutide) had 59 reported deaths and 48,148 adverse reaction reports."

vs

"For semaglutide (Wegovy), 48,089 adverse reactions were reported, including 59 deaths."

The claims provide different totals for Wegovy (semaglutide) adverse reaction reports (48,089 vs 48,148).
"For liraglutide (Saxenda), 4,491 adverse reactions were reported, including 37 deaths."

vs

"Saxenda (liraglutide) had 37 reported deaths and 4,528 adverse reaction reports."

The claims provide different totals for Saxenda (liraglutide) adverse reaction reports (4,491 vs 4,528).

[DISPUTED] For tirzepatide (Mounjaro), 106,189 adverse reactions were reported, including 120 deaths.
[DISPUTED] For semaglutide (Wegovy), 48,089 adverse reactions were reported, including 59 deaths.
[DISPUTED] For liraglutide (Saxenda), 4,491 adverse reactions were reported, including 37 deaths.
[DISPUTED] Wegovy (semaglutide) had 59 reported deaths and 48,148 adverse reaction reports.
[DISPUTED] Saxenda (liraglutide) had 37 reported deaths and 4,528 adverse reaction reports.
[● 18 SOURCES] Nestlé views the rise of GLP-1 weight-loss drugs as a significant business opportunity rather than a threat.
[● 18 SOURCES] Nestlé is using artificial intelligence and the 'Food Genie' platform to analyze clinical research and develop new recipes.
[● 12 SOURCES] Approximately 16 million Americans are currently taking GLP-1 medicines.
[● 11 SOURCES] Anvisa may approve up to eight new liraglutide and semaglutide pens by the end of 2026.

Timeline

1 day ago

[HEALTH] 3 sources
NYU Langone study links GLP-1 drugs to increased male hair loss risk
A study from NYU Langone Health finds that men genetically predisposed to male-pattern baldness may face a 7 percent increased risk of hair loss when using GLP-1 weight loss drugs like Ozempic and Wegovy.
1 day ago

[HEALTH] 7 sources
US GLP-1 weight loss prescriptions for children surge 300-fold
A study shows GLP-1 weight loss medication prescriptions for U.S. children under 12 have surged over 300-fold since 2019, highlighting rising obesity treatment and significant access disparities.
1 day ago

[HEALTH] 2 sources
GLP-1 weight loss medications and the risks of rapid weight regain
Research shows rapid weight regain after stopping GLP-1 medications like Ozempic, while some seek natural alternatives like berberine to manage metabolic health and weight.
2 days ago

[HEALTH] 2 sources
GLP-1 medications linked to reduced infection risk and improved sleep apnea
New research suggests GLP-1 medications like Ozempic and tirzepatide may reduce risks of serious infections like tuberculosis and significantly alleviate obstructive sleep apnea symptoms.
3 days ago

[HEALTH] 2 sources
Weight loss injections: How semaglutide and other drugs manage obesity
Weight loss injections like semaglutide mimic fullness hormones to treat obesity, but experts warn of metabolic defenses that make maintaining weight loss difficult once treatment stops.
3 days ago

[BUSINESS] 2 sources
GLP-1 weight-loss drugs drive shifts in fashion and food industries
GLP-1 weight-loss drugs are reshaping US markets, causing fashion brands like H&M to reduce larger clothing sizes and driving food producers like Groupe Bel to focus on high-protein, nutrient-dense products.
3 days ago

[HEALTH] 12 sources
NYU Langone Health study links GLP-1 drugs to male hair loss risk
A study by NYU Langone Health suggests GLP-1 drugs like Ozempic may increase the risk of male-pattern hair loss by 7% in genetically predisposed men.
6 days ago

[HEALTH] 7 sources
Brazil faces surge in illegal GLP-1 weight loss drug smuggling
Brazil faces a massive rise in illegal GLP-1 weight loss drug smuggling, with seizures jumping to over 60,000 units in 2025 and linked to thousands of health complications and suspected deaths.
6 days ago

[HEALTH] 3 sources
Obesity weight loss drugs investigated for potential cancer risk reduction
Medical experts are studying if GLP-1 receptor agonists used for weight loss can reduce cancer risks associated with obesity, which contributes to 4-8% of global cancer cases.
6 days ago

[HEALTH] 5 sources
GLP-1 medications face increased regulatory scrutiny in India and Japan
Health regulators in India and Japan are tightening oversight of GLP-1 weight-loss drugs to combat illegal resale, misleading advertising, and unsupervised use for cosmetic purposes.
7 days ago

[HEALTH] 7 sources
GLP-1 market shifts as Novo Nordisk partners with Vivani Medical
Novo Nordisk partners with Vivani Medical to compete with Eli Lilly in the GLP-1 market, while UC Berkeley researchers discover TOFA, a compound that may promote weight loss without muscle loss.
8 days ago

[HEALTH] 3 sources
GLP-1 medications: New studies highlight sexual function and patient concerns
New research and social media analysis reveal complex side effects of GLP-1 drugs, including improved sexual function in some women and a high patient interest in energy levels and breath quality.
8 days ago

[HEALTH] 2 sources
Ozempic demand rises in Spain amid reports of fraudulent weight-loss scams
As GLP-1 medication prescriptions rise in A Coruña, Spain, the OCU warns of fraudulent ‘OzemPil’ ads on Instagram mimicking Ozempic to deceive consumers.
9 days ago

[HEALTH] 3 sources
GLP-1 users increase fitness spending and show behavioral shifts
GLP-1 users spend nearly four times more on fitness than non-users and may experience broader behavioral shifts, including reduced compulsions for alcohol and shopping.
9 days ago

[HEALTH] 2 sources
GLP-1 drugs show potential benefits for bipolar disorder and weight maintenance
Research indicates GLP-1 drugs like semaglutide may reduce psychiatric hospitalizations for bipolar disorder patients, while new experimental molecules aim to prevent weight regain after stopping GLP-1 therapy.
9 days ago

[HEALTH] 4 sources
GLP-1 medications expand clinical uses amid warnings over misuse
GLP-1 medications like Ozempic and Mounjaro are gaining approvals for cardiovascular and renal health, but pediatricians warn of risks from misuse among youth for aesthetic purposes.
11 days ago

[HEALTH] 2 sources
Medical experts warn against unsupervised GLP-1 weight loss injections
Medical experts warn that GLP-1 weight loss injections must be used under strict doctor supervision to avoid serious risks to the pancreas, gallbladder, and digestive system.
11 days ago

[HEALTH] 5 sources
GLP-1 drugs drive protein demand and unregulated semaglutide sales
GLP-1 drugs like Ozempic are driving demand for high-protein dairy products while simultaneously fueling an unregulated online market for semaglutide sold as research chemicals in Poland.
12 days ago

[HEALTH] 2 sources
Protein intake and GLP-1 medications impact appetite and libido
Research explores how high protein intake can naturally regulate appetite and weight, while noting that GLP-1 medications may cause side effects like reduced libido by affecting brain reward systems.
12 days ago

[HEALTH] 3 sources
GLP-1 drugs linked to lower tuberculosis risk in diabetes patients
Studies suggest GLP-1 receptor agonists used for type 2 diabetes may lower tuberculosis risk by improving glycemic control and reducing systemic inflammation in high-risk patients.
13 days ago

[HEALTH] 4 sources
GLP-1 medications linked to rapid facial aging and health risks
Medical experts warn of ‘Ozempic face’—rapid facial aging caused by quick weight loss from GLP-1 drugs—and the health risks of using medications like Ozempic for off-label cosmetic purposes.
13 days ago

[HEALTH] 2 sources
FDA reports over 1,700 adverse events involving compounded GLP-1 drugs
The FDA has received over 1,700 adverse event reports related to compounded GLP-1 drugs like semaglutide and tirzepatide, amid rising reports of dosing errors and exposure cases.
13 days ago

[BUSINESS] 5 sources
GLP-1 weight loss drugs reshape food markets in Brazil and France
GLP-1 weight loss drugs are reshaping consumer habits in Brazil and France, driving demand for specialized healthy food products and signaling a massive potential market for pharmaceutical treatments.
14 days ago

[HEALTH] 11 sources
United Kingdom launches Foundayo daily weight-loss and diabetes pill
The UK is the first European country to launch Foundayo, a daily oral pill by Eli Lilly for Type 2 diabetes and weight loss, providing an alternative to injectable treatments.
14 days ago

[HEALTH] 13 sources
GLP-1 medications drive global shifts in healthcare and consumer spending
The global surge in GLP-1 weight-loss medications is transforming pharmaceutical markets, altering consumer food spending habits, and driving new developments in drug delivery and biotechnology.
15 days ago

[HEALTH] 2 sources
GLP-1 receptor agonists show potential for IBD and liver protection
New studies suggest GLP-1 receptor agonists like semaglutide and tirzepatide may improve outcomes for inflammatory bowel disease and provide protective effects for the liver.
17 days ago

[HEALTH] 3 sources
GLP-1 weight-loss programs combine medication with lifestyle support
GLP-1 weight-loss programs combine medications like semaglutide with nutrition, exercise, and medical coaching to support long-term weight maintenance and improved metabolic health.
18 days ago

[HEALTH] 23 sources
GLP-1 medications reshape healthcare markets and consumer habits
The surge in GLP-1 weight-loss drug use is transforming healthcare, reducing bariatric surgeries, and driving new consumer markets for muscle-preservation supplements while raising safety concerns.
19 days ago

[HEALTH] 16 sources
GLP-1 medications show metabolic benefits and emerging side effects
GLP-1 medications like semaglutide and tirzepatide offer metabolic and cardiovascular benefits beyond weight loss, though experts warn of side effects like hair loss and specific oral administration rules.
20 days ago

[BUSINESS] 2 sources
UK consumer demand shifts following weight-loss pill approval
UK consumers are increasingly considering weight-loss pills over injections, potentially shifting spending patterns toward health and wellness sectors as GLP-1 medications gain popularity.
20 days ago

[BUSINESS] 25 sources
Nestlé develops new products for GLP-1 weight-loss drug users
Nestlé is using AI and nutritional science to develop new products targeting the side effects of GLP-1 weight-loss drugs, such as muscle loss and facial fat reduction.
21 days ago

[BUSINESS] 6 sources
GLP-1 weight-loss drugs drive shifts in Brazilian retail and bridal markets
The popularity of GLP-1 weight-loss drugs is altering consumer trends in Brazil, impacting sportswear sales toward smaller sizes and forcing bridal ateliers to redesign dresses due to rapid weight loss.
21 days ago

[HEALTH] 3 sources
Nutritional guidance for GLP-1 weight loss medication users
Experts warn that GLP-1 weight loss drugs like Ozempic require a nutrient-dense diet to prevent muscle loss, hair loss, and exhaustion caused by rapid calorie reduction.
21 days ago

[HEALTH] 16 sources
GLP-1 medications show expanding benefits for diabetes and obesity treatment
Clinical studies and new drug rollouts show GLP-1 medications like semaglutide are transforming diabetes and obesity treatment, offering benefits for weight loss, inflammation, and cardiovascular health.
22 days ago

[HEALTH] 2 sources
Dominican Republic: High costs of weight-loss drugs drive black market risks
High costs for GLP-1 weight-loss drugs like Ozempic in the Dominican Republic are limiting access and driving patients toward dangerous black market alternatives.
23 days ago

[HEALTH] 3 sources
GLP-1 weight loss drugs require professional monitoring to ensure health
As GLP-1 weight loss drugs enter mainstream use, experts warn that professional monitoring is essential to ensure users lose fat rather than muscle and to manage metabolic changes safely.
23 days ago

[HEALTH] 4 sources
GLP-1 weight loss drugs face sustainability and muscle loss concerns
GLP-1 weight loss drugs like Ozempic are effective but face challenges, including potential muscle mass loss and the difficulty of maintaining results without significant lifestyle changes.
24 days ago

[BUSINESS] 4 sources
GLP-1 drugs reshape obesity market and consumer spending
The surge in GLP-1 obesity drugs is transforming the pharmaceutical market and consumer habits, with the sector projected to reach $100 billion annually by 2030.
24 days ago

[HEALTH] 2 sources
Breast cancer research highlights GLP-1 benefits and precision medicine
Research suggests GLP-1 weight-loss drugs may be linked to a 30% lower breast cancer risk, while clinical advancements in precision medicine are improving targeted treatments and patient quality of life.
24 days ago

[HEALTH] 4 sources
Weight loss discussions focus on GLP-1 medications and muscle preservation
Medical discussions around weight loss focus on the importance of muscle preservation and thorough health assessments when considering GLP-1 medications or alternative supplements like Calocurb.
25 days ago

[HEALTH] 4 sources
GLP-1 drugs linked to increased risk of hair loss in new study
A study involving over 12,000 patients suggests GLP-1 receptor agonists like Ozempic may increase the risk of non-scarring alopecia, potentially due to rapid weight loss or nutritional deficiencies.
26 days ago

[HEALTH] 10 sources
GLP-1 medications expand therapeutic uses and impact skin health
GLP-1 medications are expanding into broader therapeutic areas like cardiovascular health, while rising usage in the US prompts concerns over adolescent safety and dermatological side effects like skin laxity.
26 days ago

[HEALTH] 4 sources
Semaglutide and obesity treatment: Medical experts address usage and myths
Medical experts clarify that GLP-1 medications like semaglutide are tools for managing chronic obesity, not miracle cures, requiring professional supervision to manage side effects and long-term health.
27 days ago

[BUSINESS] 5 sources
GLP-1 medications drive R$ 27 billion market shift in Brazil
GLP-1 weight-loss medications are driving a R$ 27 billion market in Brazil, reshaping consumer habits in food, fashion, and fitness while raising concerns over counterfeit drug safety.
27 days ago

[HEALTH] 2 sources
New obesity classification models and oral GLP-1 drug developments
Scientists propose new obesity classification methods based on organ damage and highlight aleniglipron, a new oral GLP-1 pill that achieved 12.1% average weight loss in clinical trials.
28 days ago

[HEALTH] 3 sources
GLP-1 medications and dietary strategies for obesity management
As GLP-1 medications like semaglutide reshape obesity treatment, experts discuss their long-term impact and how dietary fiber and protein can naturally stimulate similar satiety hormones.
28 days ago

[HEALTH] 3 sources
GLP-1 weight loss drugs linked to increased hair loss risk
Studies link GLP-1 weight loss drugs like Ozempic and Wegovy to increased hair loss risks, likely due to rapid weight loss and physiological stress rather than direct chemical effects.
28 days ago

[HEALTH] 7 sources
GLP-1 drugs linked to lower fracture risk and reduced alcohol cravings
New studies suggest GLP-1 weight-loss drugs may reduce the risk of bone fractures by 21% and potentially decrease cravings and heavy drinking days in individuals with alcohol use disorder.
29 days ago

[HEALTH] 2 sources
GLP-1 weight-loss medications linked to reduced alcohol consumption
Research indicates that GLP-1 weight-loss drugs like Ozempic and Wegovy may reduce alcohol cravings and heavy drinking by affecting the brain's reward response.
30 days ago

[BUSINESS] 6 sources
GLP‑1 Weight‑Loss Drugs Cut Krispy Kreme Sales and Shift Retail Spending
GLP‑1 drugs like Ozempic, used by about 11 % of U.S. adults, are lowering doughnut demand, hurting Krispy Kreme and prompting retailers to shift toward healthier foods, beverages and apparel sales.
about 1 month ago

[HEALTH] 2 sources
Taiwan University Study Finds GLP-1 Weight‑Loss Drugs Cut Obesity‑Related Cancer Risk by 41%
A Taiwan university study using U.S. health data found GLP‑1 weight‑loss drugs reduced the risk of 13 obesity‑related cancers by 41% over two years.
about 1 month ago

[HEALTH] 16 sources
Brazil's Anvisa bans unregistered weight‑loss drugs, flags falsified Nebido lot and restricts Acanne cannabis products
Anvisa’s 6 Aug 2026 resolution bans three unregistered weight‑loss drugs, flags a falsified Nebido lot, and restricts all Acanne cannabis products to protect public health in Brazil.
about 1 month ago

[HEALTH] 29 sources
UK regulator reports over 200 deaths linked to GLP‑1 weight‑loss drugs
MHRA reports 216 suspected death links and over 150,000 adverse reaction reports for GLP‑1 weight‑loss drugs, but says reports do not prove causation.
about 1 month ago

[HEALTH] 2 sources
GLP‑1 weight‑loss drugs associated with increased hair‑loss risk
A BMJ study finds GLP‑1 drugs like Ozempic raise hair‑loss risk by 37‑68% in type‑2 diabetes patients, though absolute risk stays low.
about 1 month ago

[HEALTH] 14 sources
GLP‑1 weight‑loss drugs drive new workplace benefits, retail battles and safety debates
GLP‑1 drugs like semaglutide and tirzepatide aid weight loss and surgery outcomes, but adherence is low. Experts urge health‑focused treatment, warn against unsafe microdosing, and note corporate coverage (Bank
about 1 month ago

[HEALTH] 16 sources
Anvisa to approve up to eight new GLP‑1 weight‑loss pens in 2026
Anvisa aims to approve up to eight new GLP‑1 pens by end‑2026, boosting competition, lowering prices and tackling illegal imports, while a SUS pilot treats 250 obese patients with free semaglutide.
about 1 month ago

[HEALTH] 4 sources
GLP‑1 Weight‑Loss Drugs Linked to Facial Changes, Hair Loss and Misuse Concerns
GLP‑1 weight‑loss drugs like Ozempic and Wegovy are linked to facial changes, hair loss and eye issues, while doctors warn they are being misused by normal‑weight people for quick weight loss.
about 1 month ago

[HEALTH] 5 sources
Brazil's SUS delays rollout of GLP‑1 weight‑loss drugs
Brazil's SUS has not adopted GLP‑1 weight‑loss pens, citing budget concerns over R$ 8 bn. With obesity affecting 25.7% of adults, the Ministry seeks faster Anvisa registration after patent expiries may lower‑c
about 1 month ago

[HEALTH] 3 sources
FDA and Indian doctors flag safety risks of compounded GLP‑1 drugs
FDA warns compounded GLP‑1 drugs may be unsafe, while Indian doctors report hair loss linked to rapid weight loss from these medications.
about 1 month ago

[HEALTH] 10 sources
Ozempic and other GLP‑1 weight‑loss drugs face new protein‑muscle guidelines, theft surge, and trademark dispute
Guidelines urge protein intake and strength training for Ozempic‑type drugs; Brazil sees a surge in thefts of these meds; Novo Nordisk loses a court bid to block a Brazilian “Ozivy” trademark.
about 1 month ago

[HEALTH] 2 sources
GLP‑1 drugs promote weight loss and appetite control, but show mixed effects on erectile health
GLP‑1 drugs like Ozempic aid weight loss and appetite control; natural foods can boost GLP‑1 too. Studies show mixed effects on erectile function and little data on libido.
about 1 month ago

[HEALTH] 12 sources
GLP-1 drugs drive global shift in obesity and diabetes treatment
GLP-1 drugs are reshaping obesity and diabetes care worldwide, with new EU oral approvals, safety monitoring, declining bariatric surgery, emerging oral agents, and rising manufacturing training demand.
about 1 month ago

[HEALTH] 3 sources
Brazil's Diabetes Treatment Shifts to Modern Drugs as GLP‑1 Hair‑Loss Risks Surface
Brazil's diabetes drug spending now leans toward modern SGLT2 and GLP‑1 therapies, while US research flags a higher alopecia risk for GLP‑1 users versus other treatments.
about 1 month ago

[HEALTH] 4 sources
GLP‑1 weight‑loss drugs spark new pet treatments and post‑diet surgery demand in Brazil
Brazilian studies show GLP‑1 drugs cause weight loss in pets, while human users of Mounjaro and Ozempic drive a surge in cosmetic‑procedure demand.
about 1 month ago

[HEALTH] 2 sources
GLP-1 weight‑loss drugs linked to hair loss and higher divorce rates
Research finds GLP‑1 weight‑loss drugs may increase hair‑loss risk and are linked to higher divorce rates as rapid weight loss affects relationships.
about 1 month ago

[HEALTH] 9 sources
GLP‑1 Weight‑Loss Drugs Face Safety Concerns Over Microdosing and Side Effects
Experts warn that microdosing GLP‑1 weight‑loss drugs is unsafe, may lessen efficacy and cause side effects like hair loss and GI issues; FDA and UK health bodies urge supervised use.
about 1 month ago

[HEALTH] 2 sources
GLP‑1 weight‑loss injection pens warned for health risks in Brazil
Brazilian health experts caution that GLP‑1 weight‑loss injection pens require medical supervision due to gastrointestinal side effects and risks to oral health like enamel erosion and cavities.
about 1 month ago

[HEALTH] 18 sources
GLP‑1 weight‑loss drugs linked to higher hair‑loss risk
BMJ research finds GLP‑1 weight‑loss drugs raise hair‑loss risk by 37‑68% versus other diabetes meds; US and UK regulators are reviewing the safety signal.
about 1 month ago

[HEALTH] 4 sources
Australia's TGA warns of rare eye disease linked to GLP‑1 weight‑loss drugs
Australia's TGA warns that GLP‑1 diabetes/obesity drugs may cause rare NAION eye disease, urging patients to stop if vision changes occur; experts also flag muscle loss risk for users without proper nutrition.
about 2 months ago

[HEALTH] 2 sources
Ozempic and Mounjaro weight‑loss drugs prompt health warnings and new food trends in Greece and the US
Greek nutritionist warns stopping Ozempic or Mounjaro without lifestyle change leads to rapid weight regain, while US firms roll out “GLP‑1‑friendly” foods marketed to drug users.
about 2 months ago

[HEALTH] 10 sources
Ozempic and GLP‑1 drugs hit insurance limits, side‑effect worries
GLP‑1 drugs like Ozempic, Wegovy and Zepbound are rated cost‑effective but US insurers limit coverage, risking billions in spending; European patients see rising reimbursement and rare side‑effects such as hair
about 2 months ago

[HEALTH] 6 sources
GLP‑1 weight‑loss drugs: diet essential for lasting results
GLP‑1 drugs like semaglutide and tirzepatide produce significant weight loss but cause GI side effects; experts say high‑protein, high‑fiber diets and hydration are crucial for long‑term success.
about 2 months ago

[HEALTH] 67 sources
GLP-1 weight‑loss drugs linked to higher hair‑loss risk
A BMJ study of 50,000 diabetics finds GLP‑1 weight‑loss drugs raise alopecia risk 37% vs SGLT‑2 and 68% vs DPP‑4, though absolute risk remains low (3‑9/1,000 yr).
about 2 months ago

[HEALTH] 3 sources
Brazil sees surge in GLP‑1 weight‑loss drug use and related health concerns
European guidelines warn of health risks from unsupervised GLP‑1 weight‑loss drugs, while 33 % of Brazilian households now use them, often without prescription, raising public‑health concerns.
about 2 months ago

[HEALTH] 8 sources
Obesity treatment: limits of dieting and the impact of GLP‑1 drugs
Experts warn that strict dieting can backfire by heightening hunger and slowing metabolism, while a Slovak woman’s year‑long use of the GLP‑1 drug Mounjaro led to a 40 kg weight loss, showing both benefits and
about 2 months ago

[BUSINESS] 24 sources
GLP‑1 Weight‑Loss Drugs Reshape U.S. Healthcare, Consumer Spending and Pharma Market
GLP‑1 weight‑loss drugs are now used by over 10 % of U.S. adults, cutting grocery spend, reshaping food and airline markets, expanding a $105 bn pharma sector, and prompting new skincare, pediatric guidelines,
about 2 months ago

[HEALTH] 3 sources
Weight‑loss lifestyle strategies gain traction over injection drugs
Health reports show people favoring calorie‑deficit, protein‑rich, macro‑tracked diet plans over injectable GLP‑1 drugs, with numerous diet options outlined and a reminder to seek professional advice.
about 2 months ago

[HEALTH] 5 sources
GLP‑1 drugs may curb alcohol cravings, Greek review finds
Greek researchers found that GLP‑1 and dual GIP/GLP‑1 drugs, used for obesity, may lower alcohol craving and intake, especially in patients with “food/alcohol noise,” but evidence remains preliminary.
about 2 months ago

[HEALTH] 2 sources
Tiger Aesthetics' AlloClae uses donor fat for cosmetic procedures
Tiger Aesthetics' AlloClae, launched in the US, uses fat from deceased donors for cosmetic injections, treating over 2,000 patients since 2025 and sparking ethical debate.
about 2 months ago

[HEALTH] 5 sources
GLP‑1 weight‑loss drugs linked to better job and relationship outcomes for women and reduced binge‑eating symptoms
Research shows GLP‑1 weight‑loss drugs improve employment and marriage prospects for women and cut binge‑eating symptoms, though long‑term effects remain uncertain.
about 2 months ago

[HEALTH] 4 sources
Turkey and Greece warn against misuse of obesity injection drugs
Turkish and Greek doctors warn that obesity‑treatment injections require prescriptions and doctor supervision, citing health risks from unsupervised use.
about 2 months ago

[HEALTH] 2 sources
Rapid Weight‑Loss Drug Ozempic Linked to Facial Skin Changes
Ozempic’s rapid weight‑loss can cause facial fat loss, creating a hollow look and accelerated skin ageing, known as “Ozempic Face.”
about 2 months ago

[HEALTH] 3 sources
GLP‑1 weight‑loss drugs Wegovy and Mounjaro face yo‑yo effect and price gaps
GLP‑1 drugs Wegovy and Mounjaro aid weight loss but may cause a yo‑yo effect after stopping; UK prices vary widely, with savings of up to £3,700 possible through price comparison.
about 2 months ago

[HEALTH] 7 sources
Turkish physician warns against unsupervised weight‑loss injection use
Turkish doctor Alpay Medetalibeyoğlu warns that obesity‑treating weight‑loss injections must be used only under medical supervision, not as a DIY cosmetic fix.
about 2 months ago

[HEALTH] 2 sources
GLP‑1 receptor agonists explored for psoriasis, eczema and wound healing
A Pharmaceutics review highlights GLP‑1 agonists, known for diabetes treatment, as promising anti‑inflammatory agents for psoriasis, eczema and chronic wound healing, but notes limited clinical data.
about 2 months ago

[HEALTH] 2 sources
GLP-1 drugs fuel celebrity weight‑loss debate and show promise in slowing biological aging
GLP‑1 drugs spark celebrity weight‑loss talk while new research shows semaglutide may slow biological aging in HIV patients.
about 2 months ago

[HEALTH] 12 sources
GLP-1 weight‑loss drugs reshape U.S. health policy and consumer markets
U.S. Medicare now covers GLP‑1 weight‑loss drugs, pushing usage to 40 million adults; overdose cases spark safety worries, while retailers and Australian food firms adapt to shifting consumer habits.
about 2 months ago

[HEALTH] 5 sources
Brazil's obesity rise fuels GLP‑1 drug scrutiny and reshapes food‑service consumer habits
Brazil's obesity surge is driving scrutiny of GLP‑1 weight‑loss drugs, clarifying their regulatory status, while changing consumer habits and prompting food‑service adaptations.
about 2 months ago

[HEALTH] 3 sources
GLP‑1 drugs linked to loss of pleasure, reduced binge‑eating and lower depression risk
GLP‑1 drugs can cause anhedonia at high doses but also reduce binge‑eating and may lower depression and bipolar disorder risk, according to case reports, a systematic review and a genetic study.
about 2 months ago

[BUSINESS] 2 sources
South Africa's iDexis appeals court order on compounded weight‑loss drugs
South Africa's iDexis seeks to overturn a High Court order halting its compounded GLP‑1 weight‑loss drugs after regulators cited safety breaches; the firm says independent tests found no issues.
about 2 months ago

[HEALTH] 4 sources
Obesity drugs spark debate over access and stigma worldwide
US experts call for stigma‑free language and broader Medicare coverage of GLP‑1 obesity drugs, while South Africa debates their impact amid high obesity rates.
about 2 months ago

[HEALTH] 11 sources
US adopts cadaver‑fat injections to restore volume lost from GLP‑1 drugs
AlloClae, a US‑marketed injectable made from cadaver fat, is used to restore volume lost after GLP‑1 weight‑loss drugs, drawing rapid uptake, high costs and ethical debate.
about 2 months ago

[HEALTH] 8 sources
GLP‑1 Weight‑Loss Drugs Trigger “Ozempic Feet” Foot Changes
GLP‑1 weight‑loss drugs can cause loss of foot fat pads and muscle, leading to skin laxity, pain, shoe‑fit issues and higher ulcer risk, especially in diabetics.
about 2 months ago

[HEALTH] 2 sources
Polish health experts say obesity drugs need lifelong lifestyle support
Experts say obesity drugs like Ozempic work only with long‑term lifestyle changes; relapse rates remain high.
about 2 months ago

[HEALTH] 8 sources
German medical advances: improved GLP‑1 weight‑loss drugs and promising glioma vaccine
German firms test longer‑acting GLP‑1 weight‑loss drugs, while a new IDH1‑targeted glioma vaccine shows high survival rates in long‑term study.
about 2 months ago

[HEALTH] 2 sources
GLP‑1 and SGLT2 drugs studied for kidney health and crime reduction
Reviews find SGLT2 inhibitors protect kidneys in diabetic CKD, while GLP‑1 drugs aid metabolism; a Rutgers study links GLP‑1 use to reduced violent crime, though causality is unclear.
about 2 months ago

[HEALTH] 5 sources
South African regulators recall unlicensed Ozempic copies
South African regulators recall unlicensed Ozempic‑type drugs made by iDexis, warning pharmacists of fines and possible licence revocation after a court order blocks the company’s semaglutide products.
about 2 months ago

[HEALTH] 3 sources
Brazilian health experts shift focus from weight loss to muscle mass and body composition
Brazilian experts now prioritize muscle preservation and body composition over weight loss in obesity and ageing, promoting GLP‑1 therapies and strength training to improve health and independence.
about 2 months ago

[HEALTH] 12 sources
Obesity drugs cut weight but do not improve quality of life, study finds
A BMJ review of 262 trials finds obesity drugs like tirzepatide cut weight up to 15% but largely fail to improve quality of life, with limited heart benefits and higher side‑effects.
about 2 months ago

[HEALTH] 3 sources
Japan warns of off‑label weight‑loss use of diabetes drug Mounjaro
Japan warns that off‑label use of diabetes drug Mounjaro for weight loss may reduce contraceptive effectiveness and pose health risks, prompting health‑ ministry advisories.

Sources

10perc.hu · 24matins.es · 24matins.fr · 6abc.com · 98fmnatal.com.br · a1lightingmagazine.com · aacs.org.au · abc17news.com · abc7chicago.com · aboutpharma.com · abradilan.com.br · acceleratedwebsystems.com · acontecebrasilia.com.br · acsh.org · activistpost.com · actualidad.rt.com · actusante.net · adabiabha.net · adventhealth.com · aeiou.pt · africa.businessinsider.com · agropolska.pl · ahdb.org.uk · aijourn.com · akeza.net · albrandswaardsdagblad.nl · aldia.cat · alfavita.gr · allurantmedical.com · alternativo.mx · am730.ca · americanbazaaronline.com · amp.krone.at · analyticsinsight.net · annalehtimedia.fi · anselmosantana.com.br · ar.vogue.me · archynetys.com · archynewsy.com · archyworldys.com · ariananews.af · army.ca · arynews.tv · ascendwrestling.com · atarde.com.br · athensmagazine.gr · athina984.gr · athletechnews.com

This summary has been updated 35 times: see revision history